HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader




Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors










« Federal Judge Grants Defendants’ Motion for Summary Judgment in “All Natural” Lawsuit | Main | FDA’s High Risk Pharmacy Inspections and Enforcement Actions: Coming to a Sterile Compounding Pharmacy Near You? »

April 11, 2013

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef017eea2a175d970d

Listed below are links to weblogs that reference The President’s FY 2014 Budget Continues Push to Curb Patent Settlement Agreements, Shorten Biologics Exclusivity; Biologics Exclusivity Faces Opposition in TPP Talks:

Comments

The comments to this entry are closed.

180-Day Exclusivity Tracker

Citizen Petition Tracker

REMS Tracker

Legislation Tracker